Citi raises Ultragenyx price target to $58 after FDA approval
Tweet Send to a Friend
Citi analyst Yigal Nochomovitz raised the price target on Ultragenyx Pharmaceutical (NASDAQ: RARE) to $58 from $45, while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
